News

Signature Diagnostics / Signature Diagnostics to Present a novel Companion Diagnostic Product Predicting Response to Cetuximab in Colorectal Cancer at the 102nd AACR Meeting in Orlando . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. ...weiter

Signature Diagnostics AG announced today that the European Patent Office (EPO) has granted a new patent providing extended protection for drug molecules licensed by the company from the Technical University of Darmstadt. The new patent (EP 1858913) covers peptide- mimetics and their use as inhibitors of the human proteasome complex. The molecules have immediate application in a variety of indications, including cancer and inflammatory disease. The company is currently seeking cooperation partners for further development of these proteasome-inhibitor drug candidates.  ...weiter

Signature Diagnostics AG announced today the appointment of Rainer Kramer as Chief Business Officer. Dr. Kramer previously held the position of Vice President Corporate Business Development at Jerini AG, where he was responsible for all licensing, partnering, and alliance management activities. Before joining Jerini, he performed various research and business development functions at MorphoSys AG, Martinsried, and Amgen Inc., Thousand Oaks. ...weiter

Signature Diagnostics / Signature Diagnostics to Use Affymetrix Microarray Technology for Advanced Colorectal Cancer Tests processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. Signature Diagnostics will commercialize first microarray-based products for detecting and predicting progression of colorectal cancer  ...weiter